secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-10-09T23:59:59+00:00
Accession:  0001549595-25-000112
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Q3 FY2025 net loss $86.4M ($1.03/share); cash $428.8M; bexobrutideg pivotal trials on track
--------------------------------------------------------------------------------

- Revenue $7.9M vs $12.6M YoY; net loss $86.4M ($1.03/sh) vs $49.0M ($0.67/sh) YoY.
- Cash and securities $428.8M (down from $609.6M at Nov 2024); R&D spend $86.1M, up 55% YoY.
- Bexobrutideg ORR 80.9% in CLL (n=47) and 84.2% in WM (n=19); pivotal trials planned H2 2025.
- Preclinical data for GS-6791 (IRAK4 degrader with Gilead) presented at EADV; IND-enabling STAT6 degrader with Sanofi.
- Collaboration revenue declined as Sanofi initial research term ended; partially offset by Pfizer milestone completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000112/0001549595-25-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000112/nrix-20251009.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer